Miruvor
Sign up
The short answer

What studies of IHHT (intermittent hypoxic-hyperoxic training) found

3papers on IHHT (intermittent hypoxic-hyperoxic training)
70people in 1 study testing IHHT (intermittent hypoxic-hyperoxic training) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, compared with another group, not randomised (low certainty), for daily functioning.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: IHHT (intermittent hypoxic-hyperoxic training) may help for long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. IHHT (intermittent hypoxic-hyperoxic training) · Long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness1 study · 70 people received IHHT (intermittent hypoxic-hyperoxic training) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised145 in the study · at baseline and at the end of the rehabilitation programme · intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of IHHT (intermittent hypoxic-hyperoxic training) on breathlessness in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. (2024)

    People in the study
    145 in the study
    Dose
    intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes
    Outcome
    Borg Scale modified Borg scale
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline values for functional endpoints (ANCOVA adjusted for baseline) ANCOVA, adjusted for baseline
    Selection of participants
    Moderate. comparison group: non-randomised, by clinical judgement of attending physician Patients were assigned as clinically judged by the attending physician to the IHHT or control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Low. missing data: not reported; no dropout due to intolerance reported No dropout of patients was recorded due to intolerance to the respiratory treatment using a breathing mask.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Fatigue1 study · 70 people received IHHT (intermittent hypoxic-hyperoxic training) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised145 in the study · at baseline and at the end of the rehabilitation programme · intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of IHHT (intermittent hypoxic-hyperoxic training) on fatigue in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. (2024)

    People in the study
    145 in the study
    Dose
    intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes
    Outcome
    FAS fatigue assessment scale (FAS)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline values for functional endpoints (ANCOVA adjusted for baseline) ANCOVA, adjusted for baseline
    Selection of participants
    Moderate. comparison group: non-randomised, by clinical judgement of attending physician Patients were assigned as clinically judged by the attending physician to the IHHT or control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Low. missing data: not reported; no dropout due to intolerance reported No dropout of patients was recorded due to intolerance to the respiratory treatment using a breathing mask.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome

Daily life and health overall

Daily functioning1 study · 70 people received IHHT (intermittent hypoxic-hyperoxic training) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information).

Compared with another group, not randomised145 in the study · at baseline and at the end of the rehabilitation programme · intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes

Daily functioning improved more than in the comparison group.

IHHT (intermittent hypoxic-hyperoxic training) may improve daily functioning in long COVID. Improvement · low certainty B

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
See the 1 study
  1. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. (2024)

    People in the study
    145 in the study
    Dose
    intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes
    Outcome
    6MWT distance 6‐min walk test (6MWT)
    Effect
    better
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: baseline values for functional endpoints (ANCOVA adjusted for baseline) ANCOVA, adjusted for baseline
    Selection of participants
    Moderate. comparison group: non-randomised, by clinical judgement of attending physician Patients were assigned as clinically judged by the attending physician to the IHHT or control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Low. missing data: not reported; no dropout due to intolerance reported No dropout of patients was recorded due to intolerance to the respiratory treatment using a breathing mask.
    Measurement of outcomes
    Low. administered or clinician-rated; assessors blinded: Y
    Selection of the reported result
    Moderate. a pre-specified primary outcome
Overall symptoms1 study · 70 people received IHHT (intermittent hypoxic-hyperoxic training) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised145 in the study · at baseline and at the end of the rehabilitation programme · intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of IHHT (intermittent hypoxic-hyperoxic training) on overall symptoms in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. (2024)

    People in the study
    145 in the study
    Dose
    intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes
    Outcome
    MCRS global score MEDIAN Corona Recovery Score (MCRS)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline values for functional endpoints (ANCOVA adjusted for baseline) ANCOVA, adjusted for baseline
    Selection of participants
    Moderate. comparison group: non-randomised, by clinical judgement of attending physician Patients were assigned as clinically judged by the attending physician to the IHHT or control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Low. missing data: not reported; no dropout due to intolerance reported No dropout of patients was recorded due to intolerance to the respiratory treatment using a breathing mask.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Quality of life1 study · 70 people received IHHT (intermittent hypoxic-hyperoxic training) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised145 in the study · at baseline and at the end of the rehabilitation programme · intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of IHHT (intermittent hypoxic-hyperoxic training) on quality of life in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. (2024)

    People in the study
    145 in the study
    Dose
    intermittent hypoxic (10–12% O2) and hyperoxic (30–35% O2) breathing, three times per week on alternate days throughout the inpatient rehabilitation period (~5 weeks); sessions 45 min included six to eight cycles of repeated short-term (3–5 min) episodes
    Outcome
    EQ‐5D analogue scale European Quality of Life 5 dimensions questionnaire and analogue scale (EQ‐5D)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline values for functional endpoints (ANCOVA adjusted for baseline) ANCOVA, adjusted for baseline
    Selection of participants
    Moderate. comparison group: non-randomised, by clinical judgement of attending physician Patients were assigned as clinically judged by the attending physician to the IHHT or control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Low. missing data: not reported; no dropout due to intolerance reported No dropout of patients was recorded due to intolerance to the respiratory treatment using a breathing mask.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome

Side effects

Stopping because of side effects1 study

All papers

  1. Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.2024 · how it is prescribed, safety only · 200 with outcome data
    Summary

    This single-cohort retrospective study with a follow-up survey investigated symptomatic treatment use and patient-reported improvement in post-COVID syndrome. It included 200 patients attending the post-COVID center of the University Hospital of Erlangen between December 2022 and July 2023, with symptoms persisting at least three months after SARS-CoV-2 infection; vaccine-related symptom onset was excluded. Baseline records captured symptomatic therapies from three months post-infection until presentation. A follow-up questionnaire was completed by 165 patients (response rate 82.5%), a mean 6.3 months (SD = 2.2) after initial consultation. Treatment duration was not reported. There was no control group; patients rated improvement within the same cohort for each therapy they used, using 0 = no improvement to 3 = very strong improvement. Among therapy users, strong to very strong improvement was reported by 12 of 38 for beta-blockers, 8 of 27 for antibiotics, 5 of 15 for plasmapheresis, and 8 of 73 for outpatient psychotherapy. Vitamins and nutritional supplements were rated 9 of 135. No between-group comparison was reported. Harms, side effects, worsening and withdrawals were not reported. The authors state that the study gives initial insights into utilization and patient-reported symptom improvement.

  2. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime